| ID Source | ID |
|---|---|
| PubMed CID | 4882 |
| CHEMBL ID | 1717890 |
| CHEBI ID | 185746 |
| SCHEMBL ID | 170388 |
| MeSH ID | M0284583 |
| Synonym |
|---|
| HSCI1_000119 |
| mls002693850 , |
| 65240-86-0 |
| nsc-73233 |
| nsc73233 |
| 2-benzoylamino-1,4-naphthoquinone |
| ppm-18 |
| NCIOPEN2_004005 |
| smr001559791 |
| n-(1,4-dioxonaphthalen-2-yl)benzamide |
| CHEBI:185746 |
| n-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide |
| HMS3085F17 |
| CHEMBL1717890 |
| nsc 73233 |
| gtpl7058 |
| nqn-1 |
| SCHEMBL170388 |
| sr-01000880847 |
| SR-01000880847-2 |
| n-[1,4-bis(oxidanylidene)naphthalen-2-yl]benzamide |
| bdbm80067 |
| n-(1,4-dioxo-2-naphthalenyl)benzamide |
| n-(1,4-diketo-2-naphthyl)benzamide |
| cid_4882 |
| n-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide |
| DTXSID80274449 |
| AKOS027422618 |
| 2-benzamido-1,4-naphthoquinone |
| 2-benzamido- 1,4-naphthoquinone |
| Q27088039 |
| CS-0065340 |
| HY-118160 |
| Class | Description |
|---|---|
| naphthoquinone | A polycyclic aromatic ketone metabolite of naphthalene. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 19.9526 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.3552 | 0.0184 | 6.8060 | 14.1254 | AID624172; AID624417 |
| BRCA1 | Homo sapiens (human) | Potency | 10.0000 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.9048 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 8.7990 | 0.0052 | 7.8098 | 29.0929 | AID588855; AID720534; AID720536; AID720537 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 14.1254 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 17.7828 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| 67.9K protein | Vaccinia virus | Potency | 7.9433 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| IDH1 | Homo sapiens (human) | Potency | 7.3078 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 3.5481 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 5.8048 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 12.5893 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 10.0000 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 5.0119 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 4.4668 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.1623 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 (µMol) | 18.4600 | 2.3700 | 54.1398 | 100.0000 | AID588689 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 (µMol) | 40.2433 | 0.8890 | 21.0286 | 71.5000 | AID504765; AID540252; AID540269 |
| caspase recruitment domain family, member 15 | Homo sapiens (human) | IC50 (µMol) | 2.0620 | 0.6215 | 4.0504 | 6.6330 | AID651553 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 (µMol) | 35.7000 | 8.8700 | 12.8518 | 17.8000 | AID504792 |
| receptor-interacting serine/threonine-protein kinase 2 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 2.0620 | 0.6215 | 4.0504 | 6.6330 | AID651553 |
| C-C chemokine receptor type 6 | Homo sapiens (human) | IC50 (µMol) | 66.6000 | 11.5000 | 14.3000 | 17.1000 | AID504728 |
| tyrosyl-DNA phosphodiesterase 2 | Homo sapiens (human) | IC50 (µMol) | 11.6690 | 0.1611 | 3.9643 | 8.0090 | AID743297 |
| Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 20.7200 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 20.7200 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
| hexokinase HKDC1 | Homo sapiens (human) | IC50 (µMol) | 3.5500 | 2.4900 | 7.7444 | 12.4000 | AID504729; AID504763 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 (µMol) | 180.0000 | 0.0001 | 0.5543 | 9.9000 | AID767912 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 (µMol) | 5.5400 | 0.0000 | 0.5376 | 9.9000 | AID1679299; AID767911 |
| putative polyprotein | IC50 (µMol) | 6.9543 | 0.2508 | 3.8283 | 8.4620 | AID720577; AID720578; AID743296 | |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 (µMol) | 49.8360 | 0.7091 | 5.0549 | 7.7510 | AID651552 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| MSRA protein | Bos taurus (cattle) | EC50 (µMol) | 34.1460 | 3.6370 | 4.0500 | 4.4630 | AID623963 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PAX8 | Homo sapiens (human) | AC50 | 4.4300 | 0.0488 | 5.4354 | 69.1700 | AID687027 |
| Skn7p | Saccharomyces cerevisiae (brewer's yeast) | AbsAC40_uM | 3.1800 | 0.6600 | 5.2696 | 18.2300 | AID624258 |
| HSP40, subfamily A [Plasmodium falciparum 3D7] | Plasmodium falciparum 3D7 | AbsAC1000_uM | 7.7740 | 0.1290 | 4.1169 | 11.3160 | AID540271 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745846 | Firefly Luciferase Counterscreen for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | |||
| AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | |||
| AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | |||
| AID1346032 | Human histone deacetylase 6 (3.5.1.- Histone deacetylases (HDACs)) | 2012 | ACS chemical biology, Feb-17, Volume: 7, Issue:2 | A novel class of small molecule inhibitors of HDAC6. |
| AID767911 | Inhibition of human recombinant HDAC6 using Ac-Leu-Gly-(AMC)Lys-Ac as substrate | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Development and therapeutic implications of selective histone deacetylase 6 inhibitors. |
| AID1679299 | Inhibition of recombinant human HDAC6 expressed in baculovirus expression system using AMC-K(Ac)GL as substrate by fluorescence method | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Recent advances in the discovery of potent and selective HDAC6 inhibitors. |
| AID767912 | Inhibition of human recombinant HDAC1 using Ac-Leu-Gly-(AMC)Lys-Ac as substrate | 2013 | Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16 | Development and therapeutic implications of selective histone deacetylase 6 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (28.57%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||